Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 64

1.

Pharmacokinetics of nilotinib in pediatric patients with Philadelphia chromosome-positive chronic myeloid leukemia or acute lymphoblastic leukemia.

Hijiya N, Zwaan CM, Rizzari C, Foa R, Abbink F, Lancaster D, Landman-Parker J, Millot F, Moppett J, Nelken B, Caterina Putti M, Tian X, Sinclair K, Santanastasio H, Buchbinder A, Kearns P.

Clin Cancer Res. 2019 Nov 1. pii: clincanres.0090.2019. doi: 10.1158/1078-0432.CCR-19-0090. [Epub ahead of print]

PMID:
31676669
2.

Clinical Pharmacokinetic and Pharmacodynamic Overview of Nilotinib, a Selective Tyrosine Kinase Inhibitor.

Tian X, Zhang H, Heimbach T, He H, Buchbinder A, Aghoghovbia M, Hourcade-Potelleret F.

J Clin Pharmacol. 2018 Dec;58(12):1533-1540. doi: 10.1002/jcph.1312. Epub 2018 Sep 4. Review.

PMID:
30179260
3.

A role for heat shock factor 1 in hypercapnia-induced inhibition of inflammatory cytokine expression.

Lu Z, Casalino-Matsuda SM, Nair A, Buchbinder A, Budinger GRS, Sporn PHS, Gates KL.

FASEB J. 2018 Jul;32(7):3614-3622. doi: 10.1096/fj.201701164R. Epub 2018 Feb 5.

4.

Immunomodulation by lipid emulsions in pulmonary inflammation: a randomized controlled trial.

Hecker M, Linder T, Ott J, Walmrath HD, Lohmeyer J, Vadász I, Marsh LM, Herold S, Reichert M, Buchbinder A, Morty RE, Bausch B, Fischer T, Schulz R, Grimminger F, Witzenrath M, Barnes M, Seeger W, Mayer K.

Crit Care. 2015 May 12;19:226. doi: 10.1186/s13054-015-0933-6.

5.

A multicenter, open-label, Phase 1 study evaluating the safety and tolerability of pegaspargase in combination with gemcitabine in advanced metastatic solid tumors and lymphoma.

Borad MJ, Babiker HM, Anthony S, Mita M, Buchbinder A, Keilani T, Grem J.

Cancer Invest. 2015 May;33(5):172-9. doi: 10.3109/07357907.2015.1019677. Epub 2015 Apr 6.

PMID:
25844818
6.

Phase 1 evaluation of EZN-2208, a polyethylene glycol conjugate of SN38, in children adolescents and young adults with relapsed or refractory solid tumors.

Norris RE, Shusterman S, Gore L, Muscal JA, Macy ME, Fox E, Berkowitz N, Buchbinder A, Bagatell R.

Pediatr Blood Cancer. 2014 Oct;61(10):1792-7. doi: 10.1002/pbc.25105. Epub 2014 Jun 24.

PMID:
24962521
7.

A phase I study of EZN-3042, a novel survivin messenger ribonucleic acid (mRNA) antagonist, administered in combination with chemotherapy in children with relapsed acute lymphoblastic leukemia (ALL): a report from the therapeutic advances in childhood leukemia and lymphoma (TACL) consortium.

Raetz EA, Morrison D, Romanos-Sirakis E, Gaynon P, Sposto R, Bhojwani D, Bostrom BC, Brown P, Eckroth E, Cassar J, Malvar J, Buchbinder A, Carroll WL.

J Pediatr Hematol Oncol. 2014 Aug;36(6):458-63. doi: 10.1097/MPH.0b013e3182a8f58f.

8.

First-in-human Phase I study of EZN-4176, a locked nucleic acid antisense oligonucleotide to exon 4 of the androgen receptor mRNA in patients with castration-resistant prostate cancer.

Bianchini D, Omlin A, Pezaro C, Lorente D, Ferraldeschi R, Mukherji D, Crespo M, Figueiredo I, Miranda S, Riisnaes R, Zivi A, Buchbinder A, Rathkopf DE, Attard G, Scher HI, de Bono J, Danila DC.

Br J Cancer. 2013 Nov 12;109(10):2579-86. doi: 10.1038/bjc.2013.619. Epub 2013 Oct 29.

9.

Randomized phase 2 study of pegylated SN-38 (EZN-2208) or irinotecan plus cetuximab in patients with advanced colorectal cancer.

Garrett CR, Bekaii-Saab TS, Ryan T, Fisher GA, Clive S, Kavan P, Shacham-Shmueli E, Buchbinder A, Goldberg RM.

Cancer. 2013 Dec 15;119(24):4223-30. doi: 10.1002/cncr.28358. Epub 2013 Sep 16.

10.

Phase I dose-escalation study of EZN-2208 (PEG-SN38), a novel conjugate of poly(ethylene) glycol and SN38, administered weekly in patients with advanced cancer.

Patnaik A, Papadopoulos KP, Tolcher AW, Beeram M, Urien S, Schaaf LJ, Tahiri S, Bekaii-Saab T, Lokiec FM, Rezaï K, Buchbinder A.

Cancer Chemother Pharmacol. 2013 Jun;71(6):1499-506. doi: 10.1007/s00280-013-2149-2. Epub 2013 Mar 30.

11.

Safety, pharmacokinetics, and activity of EZN-2208, a novel conjugate of polyethylene glycol and SN38, in patients with advanced malignancies.

Kurzrock R, Goel S, Wheler J, Hong D, Fu S, Rezai K, Morgan-Linnell SK, Urien S, Mani S, Chaudhary I, Ghalib MH, Buchbinder A, Lokiec F, Mulcahy M.

Cancer. 2012 Dec 15;118(24):6144-51. doi: 10.1002/cncr.27647. Epub 2012 Jun 6.

12.

Activin A: a mediator governing inflammation, immunity, and repair.

Mayer K, Buchbinder A, Morty RE.

Am J Respir Crit Care Med. 2012 Feb 15;185(4):350-2. doi: 10.1164/rccm.201112-2210ED. No abstract available.

PMID:
22336674
13.

Hydrocarbon on Carbon: Coherent Vibrational Spectroscopy of Toluene on Graphite.

Achtyl JL, Buchbinder AM, Geiger FM.

J Phys Chem Lett. 2012 Feb 2;3(3):280-2. doi: 10.1021/jz2016796. Epub 2012 Jan 11.

PMID:
26285839
14.

Identification of binding sites for acetaldehyde adsorption on titania nanorod surfaces using CIMS.

Finkelstein-Shapiro D, Buchbinder AM, Vijayan B, Bhattacharyya K, Weitz E, Geiger FM, Gray KA.

Langmuir. 2011 Dec 20;27(24):14842-8. doi: 10.1021/la2025457. Epub 2011 Nov 23.

PMID:
22040122
15.

Displacement of hexanol by the hexanoic acid overoxidation product in alcohol oxidation on a model supported palladium nanoparticle catalyst.

Buchbinder AM, Ray NA, Lu J, Van Duyne RP, Stair PC, Weitz E, Geiger FM.

J Am Chem Soc. 2011 Nov 9;133(44):17816-23. doi: 10.1021/ja2067274. Epub 2011 Oct 17.

PMID:
21919461
16.

When the solute becomes the solvent: orientation, ordering, and structure of binary mixtures of 1-hexanol and cyclohexane over the (0001) α-Al2O3 surface.

Buchbinder AM, Weitz E, Geiger FM.

J Am Chem Soc. 2010 Oct 20;132(41):14661-8. doi: 10.1021/ja1068504.

PMID:
20866078
17.

Association of mannose-binding lectin deficiency with acute invasive aspergillosis in immunocompromised patients.

Lambourne J, Agranoff D, Herbrecht R, Troke PF, Buchbinder A, Willis F, Letscher-Bru V, Agrawal S, Doffman S, Johnson E, White PL, Barnes RA, Griffin G, Lindsay JA, Harrison TS.

Clin Infect Dis. 2009 Nov 15;49(10):1486-91. doi: 10.1086/644619.

PMID:
19827955
18.

Atmospheric heterogeneous stereochemistry.

Stokes GY, Chen EH, Buchbinder AM, Paxton WF, Keeley A, Geiger FM.

J Am Chem Soc. 2009 Sep 30;131(38):13733-7. doi: 10.1021/ja904206t.

PMID:
19772364
19.

Heterogeneous ozone oxidation reactions of 1-pentene, cyclopentene, cyclohexene, and a menthenol derivative studied by sum frequency generation.

Stokes GY, Buchbinder AM, Gibbs-Davis JM, Scheidt KA, Geiger FM.

J Phys Chem A. 2008 Nov 20;112(46):11688-98. doi: 10.1021/jp803277s. Epub 2008 Oct 23.

PMID:
18942815
20.

Photochemistry of the indoor air pollutant acetone on Degussa P25 TiO2 studied by chemical ionization mass spectrometry.

Schmidt CM, Buchbinder AM, Weitz E, Geiger FM.

J Phys Chem A. 2007 Dec 20;111(50):13023-31. Epub 2007 Nov 22.

PMID:
18031025
21.

Preterm premature rupture of membranes in human immunodeficiency virus-infected women: a novel case series.

Aagaard-Tillery KM, Lin MG, Lupo V, Buchbinder A, Ramsey PS.

Infect Dis Obstet Gynecol. 2006;2006:53234.

22.

Beckwith-Wiedemann syndrome presenting with an elevated triple screen in the second trimester of pregnancy.

Aagaard-Tillery KM, Buchbinder A, Boente MP, Ramin KD.

Fetal Diagn Ther. 2007;22(1):18-22. Epub 2006 Sep 21.

PMID:
17003550
23.

Celecoxib treatment alters the gene expression profile of normal colonic mucosa.

Glebov OK, Rodriguez LM, Lynch P, Patterson S, Lynch H, Nakahara K, Jenkins J, Cliatt J, Humbyrd CJ, Denobile J, Soballe P, Gallinger S, Buchbinder A, Gordon G, Hawk E, Kirsch IR.

Cancer Epidemiol Biomarkers Prev. 2006 Jul;15(7):1382-91.

24.

Distinguishing right from left colon by the pattern of gene expression.

Glebov OK, Rodriguez LM, Nakahara K, Jenkins J, Cliatt J, Humbyrd CJ, DeNobile J, Soballe P, Simon R, Wright G, Lynch P, Patterson S, Lynch H, Gallinger S, Buchbinder A, Gordon G, Hawk E, Kirsch IR.

Cancer Epidemiol Biomarkers Prev. 2003 Aug;12(8):755-62.

25.

Is the use of insulin lispro safe in pregnancy?

Buchbinder A, Miodovnik M, Khoury J, Sibai BM.

J Matern Fetal Neonatal Med. 2002 Apr;11(4):232-7. Review.

PMID:
12375676
26.

Adverse perinatal outcomes are significantly higher in severe gestational hypertension than in mild preeclampsia.

Buchbinder A, Sibai BM, Caritis S, Macpherson C, Hauth J, Lindheimer MD, Klebanoff M, Vandorsten P, Landon M, Paul R, Miodovnik M, Meis P, Thurnau G; National Institute of Child Health and Human Development Network of Maternal-Fetal Medicine Units.

Am J Obstet Gynecol. 2002 Jan;186(1):66-71.

PMID:
11810087
27.

Leptin in the ovine fetus correlates with fetal and placental size.

Buchbinder A, Lang U, Baker RS, Khoury JC, Mershon J, Clark KE.

Am J Obstet Gynecol. 2001 Oct;185(4):786-91.

PMID:
11641652
28.

Gene therapy in human cancer: report of human clinical trials.

Wasil T, Buchbinder A.

Cancer Invest. 2000;18(8):740-6. Review. No abstract available.

PMID:
11107444
29.

Is insulin lispro associated with the development or progression of diabetic retinopathy during pregnancy?

Buchbinder A, Miodovnik M, McElvy S, Rosenn B, Kranias G, Khoury J, Siddiqi TA.

Am J Obstet Gynecol. 2000 Nov;183(5):1162-5.

PMID:
11084559
30.

[Comparative analysis of the proliferative capacity of cholesteatomas].

Bernal Sprekelsen M, Ebmeyer J, Buchbinder A, Sudhoff H.

Acta Otorrinolaringol Esp. 2000 May;51(4):299-307. Spanish.

PMID:
10984952
31.

Ig V gene mutation status and CD38 expression as novel prognostic indicators in chronic lymphocytic leukemia.

Damle RN, Wasil T, Fais F, Ghiotto F, Valetto A, Allen SL, Buchbinder A, Budman D, Dittmar K, Kolitz J, Lichtman SM, Schulman P, Vinciguerra VP, Rai KR, Ferrarini M, Chiorazzi N.

Blood. 1999 Sep 15;94(6):1840-7.

PMID:
10477712
32.

A phase I study of sequential vinorelbine followed by paclitaxel.

Budman DR, Weiselberg L, O'Mara V, Buchbinder A, Lichtman SM, Donahue L, Adams LM.

Ann Oncol. 1999 Jul;10(7):861-3.

PMID:
10470436
33.

Secondary hemochromatosis as a long-term complication of the treatment of hematologic malignancies.

Lichtman SM, Attivissimo L, Goldman IS, Schuster MW, Buchbinder A.

Am J Hematol. 1999 Aug;61(4):262-4.

34.

Acquired factor VIII inhibitors--successful treatment with an oral outpatient regimen.

Bayer RL, Lichtman SM, Allen SL, Budman DR, Buchbinder A, Fetten J, Kolitz J, Loscalzo J.

Am J Hematol. 1999 Jan;60(1):70-1.

35.

Clonal expansion within the CD4+CD57+ and CD8+CD57+ T cell subsets in chronic lymphocytic leukemia.

Serrano D, Monteiro J, Allen SL, Kolitz J, Schulman P, Lichtman SM, Buchbinder A, Vinciguerra VP, Chiorazzi N, Gregersen PK.

J Immunol. 1997 Feb 1;158(3):1482-9.

PMID:
9013995
36.

Rearrangement and expression of MDM2 oncogene in chronic lymphocytic leukemia.

Huang YQ, Raphael B, Buchbinder A, Li JJ, Zhang WG, Friedman-Kien AE.

Am J Hematol. 1994 Oct;47(2):139-41.

PMID:
8092130
37.

Synergistic neutralization of human immunodeficiency virus type 1 by combinations of human monoclonal antibodies.

Laal S, Burda S, Gorny MK, Karwowska S, Buchbinder A, Zolla-Pazner S.

J Virol. 1994 Jun;68(6):4001-8.

38.

Human monoclonal antibodies to HIV-1 define synergistic activities leading to enhanced neutralization.

Zolla-Pazner S, Laal S, Burda S, Buchbinder A.

Antibiot Chemother (1971). 1994;46:38-47. Review. No abstract available.

PMID:
7826038
39.

An unusual and unreported toxicity to erythropoietin.

Buchbinder A, Adler H, Ballard H.

Am J Hematol. 1993 Apr;42(4):412-3. No abstract available.

PMID:
8494005
40.
41.

Repertoire of neutralizing human monoclonal antibodies specific for the V3 domain of HIV-1 gp120.

Gorny MK, Xu JY, Karwowska S, Buchbinder A, Zolla-Pazner S.

J Immunol. 1993 Jan 15;150(2):635-43.

PMID:
7678279
42.

Neutralization of diverse human immunodeficiency virus type 1 variants by an anti-V3 human monoclonal antibody.

Gorny MK, Conley AJ, Karwowska S, Buchbinder A, Xu JY, Emini EA, Koenig S, Zolla-Pazner S.

J Virol. 1992 Dec;66(12):7538-42.

43.

The absence of Tat sequences in tissues of HIV-negative patients with epidemic Kaposi's sarcoma.

Huang YQ, Buchbinder A, Li JJ, Nicolaides A, Zhang WG, Friedman-Kien AE.

AIDS. 1992 Oct;6(10):1139-42.

PMID:
1466845
44.

Clinical aspects of Kaposi's sarcoma.

Buchbinder A, Friedman-Kien AE.

Curr Opin Oncol. 1992 Oct;4(5):867-74. Review.

PMID:
1457502
45.

Synergy between human monoclonal antibodies to HIV extends their effective biologic activity against homologous and divergent strains.

Buchbinder A, Zolla-Pazner S, Karwowska S, Gorny MK, Burda ST.

AIDS Res Hum Retroviruses. 1992 Aug;8(8):1395. No abstract available.

PMID:
1466965
46.

Production of human monoclonal antibodies specific for conformational and linear non-V3 epitopes of gp120.

Karwowska S, Gorny MK, Buchbinder A, Gianakakos V, Williams C, Fuerst T, Zolla-Pazner S.

AIDS Res Hum Retroviruses. 1992 Jun;8(6):1099-106.

PMID:
1380257
47.

Synergy between human monoclonal antibodies to HIV extends their effective biologic activity against homologous and divergent strains.

Buchbinder A, Karwowska S, Gorny MK, Burda ST, Zolla-Pazner S.

AIDS Res Hum Retroviruses. 1992 Apr;8(4):425-7. No abstract available.

PMID:
1599752
48.

Kinetics of expression of multiply spliced RNA in early human immunodeficiency virus type 1 infection of lymphocytes and monocytes.

Klotman ME, Kim SY, Buchbinder A, DeRossi A, Baltimore D, Wong-Staal F.

Proc Natl Acad Sci U S A. 1992 Feb 1;89(3):1148. No abstract available.

49.

Kinetics of expression of multiply spliced RNA in early human immunodeficiency virus type 1 infection of lymphocytes and monocytes.

Klotman ME, Kim S, Buchbinder A, DeRossi A, Baltimore D, Wong-Staal F.

Proc Natl Acad Sci U S A. 1991 Jun 1;88(11):5011-5. Erratum in: Proc Natl Acad Sci U S A. 1992 Feb 1;89(3):1148.

50.

Clinical aspects of epidemic Kaposi's sarcoma.

Buchbinder A, Friedman-Kien AE.

Cancer Surv. 1991;10:39-52. Review.

PMID:
1821322

Supplemental Content

Loading ...
Support Center